Join Economist editors and thought leaders from across the health-care ecosystem to discuss and debate how innovation can be scaled across policy and financing, prevention, early detection, treatment and long-term management of this deadly disease. Don’t miss the opportunity to network with 200 of your peers and those making major progress in the war on cancer. Download the event brochure.
While advances in cancer treatment have come a long way, cancer remains among the leading causes of death worldwide. Though the promise of technology allowing for faster, more precise treatment and more collaborative health care models is inching us closer to victory, scaling the progress made thus far remains a critical next step.
Price is among the principal barriers to providing universal access to quality cancer treatment. In the US, it costs over two billion dollars to bring a new cancer drug to market. While the return on investing in some of these therapies remains a largely polarized issue, in an age of infinite technological possibilities, scaling such innovations becomes more of a reality. How can technology be used to lower the costs associated with drug development, distribution and administration? How can big pharma work collaboratively with disruptive startups to operate at a more competitive cost, and with stronger scalability? What can be learned from oncologists and pioneering genomic researchers from outside the United States working with sparse budgets? How can stronger dialogues and partnerships among the public sector, civil society, patient association groups and the private sector be used to catalyze breakthrough innovation and speed up the delivery of new cancer medicines, better prevention, better diagnostics, and better patient care?
Send this to a friend